Immunotherapy Making Its Mark on Head and Neck Cancer – Targeted Oncology
|
Immunotherapy Making Its Mark on Head and Neck Cancer
Targeted Oncology Following the approval of 2 immunotherapy agents, pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of patients with head and neck cancer (HNC) over the last 6 months, immunotherapy is making its mark on the treatment paradigm for … |
